Agelastatin A: a novel inhibitor of osteopontin-mediated adhesion, invasion, and colony formation
Open Access
- 1 March 2008
- journal article
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- Vol. 7 (3) , 548-558
Abstract
Effective inhibitors of osteopontin (OPN)–mediated neoplastic transformation and metastasis are still lacking. (-)-Agelastatin A is a naturally occurring oroidin alkaloid with powerful antitumor effects that, in many cases, are superior to cisplatin in vitro. In this regard, past comparative assaying of the two agents against a range of human tumor cell lines has revealed that typically (-)-agelastatin A is 1.5 to 16 times more potent than cisplatin at inhibiting cell growth, its effects being most pronounced against human bladder, skin, colon, and breast carcinomas. In this study, we have investigated the effects of (-)-agelastatin A on OPN-mediated malignant transformation using mammary epithelial cell lines. Treatment with (-)-agelastatin A inhibited OPN protein expression and enhanced expression of the cellular OPN inhibitor, Tcf-4. (-)-Agelastatin A treatment also reduced β-catenin protein expression and reduced anchorage-independent growth, adhesion, and invasion in R37 OPN pBK-CMV and C9 cell lines. Similar effects were observed in MDA-MB-231 and MDA-MB-435s human breast cancer cell lines exposed to (-)-agelastatin A. Suppression of Tcf-4 by RNA interference (short interfering RNA) induced malignant/invasive transformation in parental benign Rama 37 cells; significantly, these events were reversed by treatment with (-)-agelastatin A. Our study reveals, for the very first time, that (-)-agelastatin A down-regulates β-catenin expression while simultaneously up-regulating Tcf-4 and that these combined effects cause repression of OPN and inhibition of OPN-mediated malignant cell invasion, adhesion, and colony formation in vitro. We have also shown that (-)-agelastatin A inhibits cancer cell proliferation by causing cells to accumulate in the G2 phase of cell cycle. [Mol Cancer Ther 2008;7(3):548–58]Keywords
This publication has 49 references indexed in Scilit:
- BRCA1 Suppresses Osteopontin-mediated Breast CancerJournal of Biological Chemistry, 2006
- Thyroid Hormone Receptor α1 Directly Controls Transcription of the β-Catenin Gene in Intestinal Epithelial CellsMolecular and Cellular Biology, 2006
- Association of S100A4 and osteopontin with specific prognostic factors and survival of patients with minimally invasive breast cancer.Clinical Cancer Research, 2006
- Molecular mechanisms of drug resistanceThe Journal of Pathology, 2005
- Ets Gene PEA3 Cooperates with β-Catenin-Lef-1 and c-Jun in Regulation of Osteopontin TranscriptionJournal of Biological Chemistry, 2004
- The Tuberin-Hamartin Complex Negatively Regulates β-Catenin Signaling ActivityJournal of Biological Chemistry, 2003
- RNA interferenceNature, 2002
- The Active Centres of Agelastatin A, a Strongly Cytotoxic Alkaloid of the Coral Sea Axinellid Sponge Agelas dendromorpha, as Determined by Comparative Bioassays with Semisynthetic DerivativesHelvetica Chimica Acta, 1996
- Conformational Preferences and Absolute Configuration of Agelastatin A, a Cytotoxic Alkaloid of the Axinellid Sponge Agelas dendromorpha from the Coral Sea, via combined molecular modelling, NMR, and exciton splitting for diamide and hydroxyamide derivativesHelvetica Chimica Acta, 1994
- The pattern of metastases in human breast cancer: Methodological aspects and influence of prognostic factorsCancer Treatment Reviews, 1990